Panacea Biotec Limited · NSE:PANACEABIO
Panacea Biotec — Investor Presentation (August 2021)
28 slides from Panacea Biotec's investor presentation, Aug 2, 2021
Slide 1: Exchange filing cover letter - Investor Presentation
~macea Biotec !hhOVt::..tt'Oh 'h swpport: of tt'fe August 02, 2021 The Manager, Listing Department BSE Limited The National Stock Exchange of India Ltd. Corporate Relationship Department, Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai - 400 051 Dalal Street, Mumb
Slide 2: Building on the Growth Momentum - Investor Presentation July 2021
BUILDING ON THE We are GROWTH We Pioneers MOMENTUM Believe in Better Health I N VE STOR P R E SE N TATION We Live Well Collaborate Live Longer 2021 We JULY Innovate To create value Private, Confidential, Circulation Restricted. All Rights Reserved
Slide 3: Disclaimer
Disclaimer This presentation contains selected information about the activities of Panacea Biotec Limited (the “Company”) as at the date of the presentation. This presentation has been prepared by the Company) for general information purposes only, without regard to any specific objectives, suitabil
Slide 4: Table of Contents
Slide 4 - 6 01 Business Overview & Highlights Business Segments 02 Slide 7 - 9 Table of Key Investment Contents Slide 10 - 19 03 Highlights PANACE A BI OT E C LI M I T E D Growth Strategies 04 Slide 20 - 23 Slide 24 - 26 05 Financial Highlights 03
Slide 5: Business Overview & Highlights
Business Overview & Highlights • OVERVIEW AND GROUP STRUCTURE • KEY MILESTONES • PANACEA BIOTEC AT A GLANCE PANACE A BI OT E C LI M I T E D 04
Slide 6: Company Overview
Company Overview Brief Background Group Structure* Incorporated in 1984, Panacea Biotec is one of the leading research-based Promoter & Promoter Group Public Shareholders 01 biotechnology company, Listed on NSE and BSE (73.59%) (26.41%) At the forefront in vaccine development with established brand
Slide 7: Our Journey
Our Journey HUMBLE BEGINNINGS SAILING THROUGH EBB & FLOW PRISM OF POSSIBILITIES 1984 2005 2006 2015 2016 Onwards 2006 : Commissioned cGMP compliant 2017 : Launch of world’s first wP based fully Founder, Promoter, Director pharmaceutical formulation facility liquid Hexavalent vaccine (DTwP-HepB- of P
Slide 8: Business Segments
Business Segments • VACCINE BUSINESS • PHARMACEUTICAL FORMULATION BUSINESS PANACE A BI OT E C LI M I T E D 07
Slide 9: Vaccines - Leading player in key pediatric vaccines
Vaccines - Leading player in key pediatric vaccines Panacea Biotec is one of the largest vaccine manufacturing Company in India 𝟔𝒕𝒉 We believe that we have played a pivotal role in eradication of polio by supplying billions of doses of WHO pre-qualified Largest Vaccine oral polio vaccine…
Slide 10: Pharmaceutical Formulations - Strong domestic franchise with export focus
Pharmaceutical Formulations - Strong domestic franchise with export focus Strong focus on niche and high growth segments - Organ Transplantation, Oncology and Diabetes management 𝟏𝟎𝒕𝒉 Operates through 4 SBUs - Transplant & Immunology, Oncotrust, Diacar Largest Pharma Domestic market 58%…
Slide 11: Key Investment Highlights
Key Investment Highlights • PIONEER IN VACCINE BUSINESS • LEADING DOMESTIC FORMULATIONS PLAYER • STATE-OF-THE-ART MANUFACTURING FACILITIES PANACEA BIOTEC LIMITED • ESTABLISHED R&D CAPABILITIES • LEVERAGING GROWTH ALLIANCES • VISIONARY PROMOTER GROUP 10
Slide 12: Key Strengths
Key Strengths Established vaccine One of the leading State-of-the-art business with strong domestic formulations manufacturing legacy player - Strong brands facilities with large in niche segments capacities Established R&D Leveraging alliances Strong Promoter Group KEY INVES TMENT HIGHLIGHTS capabi
Slide 13: Established vaccine business with strong legacy
Established vaccine business with strong legacy Established vaccine development capability with three firsts to its credit EasySix Easyfive-TT T-OPV, bOPV, DTwP-Hib-HepB-IPV DTwP-Hib-HepB mOPV1, mOPV3 Fully Liquid Hexavalent Vaccine Fully Liquid Pentavalent Vaccine Oral Polio Vaccines First to launc
Slide 14: Leading domestic formulations player - Strong brands in niche segments
Leading domestic formulations player - Strong brands in niche segments SBU Transplantation & Immunology Diacar Alpha Oncotrust Procare Therapy Anti-hemorrhoid, Gastro, Anti- Organ Transplantation Anti-diabetic Oncology inflammatory, Osteoarthritis etc. FY21 Revenue (% of Total Domestic 35% 33% 2% 22
Slide 15: State-of-the-art manufacturing facilities - Vaccine
State-of-the-art manufacturing facilities with large capacities Prefilled Syringe Liquid filled Vials Lyophilized Vials Drug substance Products • Baddi plant has three filling lines – pre-filled syringe (“PFS”), Vials, & lyophilized vials VACCINE Manufacturing Setup • Backward integrated vaccine man
Slide 16: State-of-the-art manufacturing facilities - Pharmaceutical Formulations
State-of-the-art manufacturing facilities with large capacities PHARMACEUTICAL FORMULATIONS Products Soft gelatine & hard gelatine capsules Sterile, cytotoxic Liquids Oral solids Topical • Baddi facility is spread across 23 acres with dedicated blocks for pharmaceutical formulations & oncology injec
Slide 17: Established R&D capabilities, brands and extensive distribution network
Established R&D capabilities & brands and extensive distribution network R&D strengths Strong brand equity in domestic market with Pan India presence and growing exports presence 80+ Team of R&D Professionals Top 50 Innovators in India1 74 Brands 12 brands ranked among top Including 60+ Scientists 7
Slide 18: Leveraging Alliances for Growth - Vaccines
Leveraging Alliances for Growth - Vaccines Collaborative approach to increase access to Innovative, Affordable and Quality vaccines for global population Russian Direct Investment National National Institutes Institutes of of Intravacc Health (NIH) Fund (RDIF) Health (NIH) Agreement signed with RD
Slide 19: Leveraging Alliances for Growth - Pharmaceutical Formulations
Leveraging Alliances for Growth – Pharmaceutical Formulations Expanding presence in regulated markets through strategic collaborations Breckenridge Pharmaceutical Apotex, Inc. Bionpharma, Inc. Inc. & Natco Pharma Ltd. Launched Prasugrel tablets in the USA Launched Tacrolimus and Rizatriptan Benz
Slide 20: Promoter Group with Cumulative Experience of 80+ years
Promoter Group with Cumulative Experience of 80+ years DR. RAJESH JAIN SANDEEP JAIN ANKESH JAIN HARSHET JAIN MANAGING DIRECTOR JOINT MANAGING DIRECTOR DIRECTOR – SALES & MARKETING HEAD BUSINESS DEVELOPMENT (BIOLOGICALS) • Directly oversees innovation • Involved in international • Oversees the Sales
Slide 21: Growth Strategies
Growth Strategies • VACCINE GROWTH STRATEGIES • PHARMA GROWTH STRATEGY PANACE A BI OT E C LI M I T E D 20
Slide 22: Growth Strategies - Vaccines
Growth Strategies - Vaccines Capitalize on Collaboration with RDIF for producing 100 mn doses. Covid-19 Technology transfer successfully completed Vaccine Registration & Validation batches in progress Opportunity Manufacturing permission received from DCGI Dengue Vaccine & Pneumococcal Con
Slide 23: Growth Strategies - Pharma
Growth Strategies - Pharma PIPELINE OF NICHE, COMPLEX & HIGH ENTRY BARRIER PRODUCTS ICH Markets Strong product pipeline - 6 ANDAs submitted and awaiting approval (USA, Europe, Aim to launch Paclitaxel protein-bound particles for Injectable suspension in USA in Q1FY2023 post Canada, receipt of fi
Slide 24: Consolidated Financial Highlights
Consolidated Financial Highlights • FINANCIAL HIGHLIGHTS PANACE A BI OT E C LI M I T E D 23
Slide 25: Financial Highlights - Consolidated
Financial Highlights - Consolidated CONSOLIDATED REVENUES TOTAL REVENUE EBITDA* ₹6,248 MN 15% ₹ Mn ₹ M ₹ M nn 772 803 6,248 -559 Net Revenue in FY21 was ₹ 6,248 Mn, up 15% YoY 5,441 909 690 4,567 FY21 Vaccine Revenue at ₹2,278 Mn; up 62% YoY 425 3,970 FY21 Pharma Revenue at ₹3,970 Mn; down 2%
Slide 26: Financial Highlights – Consolidated Profit & Loss Statement
Financial Highlights – Consolidated Profit & Loss Statement VACCINE PHARMACEUTICAL CONSOLIDATED KEY PERFORMANCE METRICS (₹ Mn) FY19 FY20 FY21 FY19 FY20 FY21 FY19 FY20 FY21 Revenue from operations 962 1,404 2,278 3,605 4,037 3,970 4,567 5,441 6,248 EBITDA# (984) (137) 113 425 909 690 (559) 772 803 EB
Slide 27: Financial Highlights – Summary of Consolidated Balance Sheet
Financial Highlights – Summary of Consolidated Balance Sheet CONSOLIDATED KEY PERFORMANCE METRICS (₹ Mn) Segmental Break up (₹ Mn) FY19 FY20 FY21 FY19 FY20 FY21 Assets Total Assets Net Fixed Assets1 8,281 6,814 6,431 Vaccine 4,721 7,078 7,164 Other Non-current Assets2 396 256 247 Pharmaceuticals 4,3
Slide 28: Thank You
THANK YOU C O N TAC T U S Panacea Biotec Limited PANACE A BI OT E C LI M I T E D B-1 Ext./G-3, Mohan Co-operative Industrial Estate, Mathura Road, New Delhi - 110044 www.panaceabiotec.com Tel: +91 – 11 – 4157 8011 Mob: +91 - 98109 04102 Email: devendergupta@panaceabiotec.com 27 Private, Confidential